| |
Dr David King brings a depth of corporate governance, capital markets and listed company board experience to Cellmid. He has previously held positions as Executive Director, Chief Executive Officer and Managing Director in a number of private and listed companies.
An expert in high growth companies Dr King has a track record in starting business ventures and developing them into attractive investment and/or take-over targets. His experience in successful start-up businesses has been instrumental in CDY’s recent acquisition of the midkine intellectual property portfolio.
Dr King is a Fellow of the Australian Institute of Company Directors, a Fellow of the Australian Institute of Geoscientists and the Australian Institute of Mining & Metallurgy (Chartered Professional, Management) and holds degrees in physics and geophysics and a PhD in Seismology from the Australian National University.
|
| |
Maria Halasz has been involved with biotechnology companies for 17 years; initially working in executive positions in biotechnology firms, then managing investment funds and later holding senior positions in corporate finance specialising in life sciences.
Prior to joining Cellmid Ms Halasz had been an adviser to an independent sector based research firm in life sciences and managed Direct Capital Group Pty Ltd, a specialist biotechnology fund. She has also been a venture partner at the Emerging Technology Fund of venture capital firm Allen & Buckeridge.
Since taking over as Chief Executive and Managing Director of Cellmid Ms Halasz has led the restructure of the business, the acquisition of the midkine intellectual property portfolio and the recapitalisation of the company.
Ms Halasz is a Member of the Australian Institute of Company Directors and holds a science degree in Microbiology and an MBA.
|
| |
Mr Robin Beaumont is a senior strategic adviser and experienced public company director. He was Chairman of Arana Therapeutics Limited, a listed biotechnology company, until the company’s recent takeover by Cephalon Inc., and was a director of antibody engineering company Evogenix Limited until its merger with Peptech Limited to form Arana Therapeutics in 2007. His life science industry experience also includes previous roles as Chairman of Select Vaccines Limited, Chairman of the Cooperative Research Centre for Diagnostics and non-executive director of GroPep Limited.
Mr Beaumont was Managing Director of the Advent venture capital group until 1998 and represented Advent’s interests as a director of Primary Health Care, Benchmark Mutual Hospital Group, The Preston Group, Tower Technology and the Ayers Rock Resort Company. He is also a former non-executive director of Ruralco Limited. Prior to joining Advent, Mr Beaumont had more than ten years of strategy consulting experience, after holding senior management positions in a large listed company.
|